Jesús Guinea, Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):59-63. doi: 10.37201/req/s01.14.2023. Epub 2023 Nov 24.
New antifungal agents are needed to overcome limitations of available ones such as poor pharmacokinetic traits, toxicity, drug-drug interactions, limited clinical efficacy, and emerging antifungal resistance. New antifungal drugs belong to well-known families (azoles, polyenes, or beta-d-glucan synthase inhibitors) or to drug families showing completely new mechanisms of action. Some drugs have a head start in terms of potential to reach the clinical setting and are here reviewed.
需要新的抗真菌药物来克服现有药物的局限性，如药代动力学特征差、毒性、药物相互作用、临床疗效有限和抗真菌耐药性的出现。新型抗真菌药物属于已知的药物家族（唑类、多烯类或β-D-葡聚糖合成酶抑制剂）或具有全新作用机制的药物家族。一些药物在进入临床应用方面具有先发优势，本文对此进行了综述。
